Edition:
United States

Cogentix Medical Inc (CGNT.OQ)

CGNT.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
15 Dec 2017
Change (% chg)

$-0.02 (-0.69%)
Prev Close
$2.91
Open
$2.91
Day's High
$2.97
Day's Low
$2.89
Volume
3,629
Avg. Vol
13,403
52-wk High
$3.25
52-wk Low
$1.55

Summary

Name Age Since Current Position

Uri Geiger

49 2016 Chairman of the Board

Darin Hammers

2016 President, Chief Executive Officer, Director

Brett Reynolds

47 2016 Chief Financial Officer, Senior Vice President, Principal Financial Officer, Principal Accounting Officer, Secretary

Kenneth Paulus

57 2015 Director

Cheryl Pegus

52 2015 Director

Lewis Pell

71 2015 Director

Kevin Roche

66 2015 Director

Nachum Shamir

63 2016 Director

Howard Zauberman

62 2015 Director

Kenneth Samet

59 2016 Independent Director

Biographies

Name Description

Uri Geiger

Dr. Uri Geiger serves as Chairman of the Board of the Company. Dr. Geiger currently serves as the Managing Partner of Accelmed. Prior to that, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components, from 2001 until 2003. Dr. Geiger has also served as the founding partner of Dragon Variation Fund, one of Israel’s first hedge funds, since 2000. Prior to returning to Israel in 1999, he gained a broad understanding and experience in capital markets working on Wall Street. Dr. Geiger was formerly an adjunct professor at Tel Aviv University’s Recanati School of Business where he lectured on private equity and venture capital and authored the books “Startup Companies and Venture Capital” and “From Concept to Wall Street”. Dr. Geiger previously served on the board of directors of EndoChoice Holdings Inc. from January 2014 until March 2016. Dr. Geiger earned his doctorate from New York’s Columbia University Center for Law & Economics, with a concentration in global equity markets. Dr. Geiger also served as a major (Ret.) in the Israeli Air force.

Darin Hammers

Mr. Darin Hammers is President, Chief Executive Officer, Director of the Company. In addition to serving as the interim Chief Executive Officer and President of the company since May 24, 2016, Mr. Hammers had served as the company’s Senior Vice President of Global Sales and Marketing since March 31, 2015 until January 4, 2016, when he was promoted to the position of Chief Operating Officer. Mr. Hammers had served as Senior Vice President of Global Sales and Marketing for Uroplasty, Inc. from September 2013 until March 31, 2015. From February 2013 until September 2013, he had served as Uroplasty’s Vice President of Global Sales. Prior to joining Uroplasty, Mr. Hammers had been the Vice President of Sales – Bard Medical Division at CR Bard from 2009 to 2013. He had held roles of increasing responsibility in sales and sales management with Boston Scientific Corporation from 1996 to 2009. Mr. Hammers holds a BS in Marketing from the University of Southern Indiana and received his MBA from Emory University.

Brett Reynolds

Mr. Brett A. Reynolds is Chief Financial Officer, Senior Vice President, Principal Financial Officer, Principal Accounting Officer, Secretary of the Company. Mr. Reynolds had previously served as Cogentix’s Senior Vice President, Chief Financial Officer and Corporate Secretary from March 31, 2015 to January 28, 2016, and had served in the same roles for Uroplasty, Inc. from August 2013 until March 31, 2015. He joined Uroplasty as Senior Vice President and Chief Financial Officer in August 2013. From 2005 until its acquisition by Baxter International Inc. in February 2012, Mr. Reynolds was the Chief Financial Officer and Vice President of Finance of Synovis Life Technologies, Inc., a publicly-held medical device manufacturer headquartered in the St. Paul, MN. From 2012 until becoming an officer of Uroplasty, Mr. Reynolds was the site leader of Baxter in the Twin Cities responsible for the remainder of the Synovis operations. Prior to Synovis, Mr. Reynolds served in executive financial positions at Chiquita Processed Foods, Arthur Andersen and Deloitte & Touche. Mr. Reynolds is a Certified Public Accountant and holds a BS in Accounting and an MBA from the University of Minnesota's Carlson School of Management.

Kenneth Paulus

Mr. Kenneth H. Paulus is an Director of the Company. Kenneth H. Paulus was named Director of Cogentix Medical when Uroplasty merged with Vision-Sciences in March 2015. He became a director of Uroplasty in October 2014. He currently serves as Chief Executive Officer of Allina Heath, a Minnesota-based health system. Before joining Allina Health in 2005, Mr. Paulus was President and Chief Executive Officer of Massachusetts-based HealthOne Care System, one of the nation's largest integrated physician organizations and a teaching and research affiliate of Harvard Medical School. Before his time at HealthOne, he served as the Chief Operating Officer of Boston-based Partners Community HealthCare/Partners HealthCare System, a teaching affiliate of Harvard Medical School that includes two of the nation's leading hospitals - Massachusetts General Hospital and Brigham and Women's Hospital.

Cheryl Pegus

Dr. Cheryl Pegus, M.D., MPH, is Director of the Company. She was Independent Director of Vision Sciences, Inc. Dr. Pegus is a Director of Glytec, a glycemic clinical software company and Strategic Advisor to HealthFleet, Inc, an online interactive prevention company. She is the 2013 President-Elect and a member of the Board of the American Heart Association (AHA) Founder’s Affiliate. Previously, she was the Chief Medical Officer for Walgreens. She has served as the General Manager and Chief Medical Officer for SymCare Personalized Health Solutions, Inc., and the Head of Clinical Products for Aetna’s Medical Products Business Unit. Dr. Pegus also served as the Medical Director for the Cardiovascular Risk Factors Group at Pfizer Pharmaceuticals. She is a Member of the Dean’s Circle at Weill Cornell Medical College. She received an M.P.H. from Columbia University School of Public Health, an M.D. from Cornell University Medical College and completed her internal medicine residency and cardiology fellowship at New York Hospital-Cornell.

Lewis Pell

Mr. Lewis C. Pell is an Director of the Company. Lewis Pell has founded over a dozen successful medical technology companies during the past three decades. In 1979, Mr. Pell founded Pentax Precision Instruments, which was sold to Asahi Optical in 1990. In 1983 he founded American Endoscopy Inc., which was sold to CR Bard in 1986. In 1984 he founded Versaflex Inc., which was sold to Medtronic Inc. in 1988. In 1989 he founded Heart Technology Corp., which went public in the U.S. in 1992 and eventually was sold to Boston Scientific in 1995. In 1991 he founded InStent Inc., which became a public company in 1995 and was sold to Medtronic in 1996. In 1994 he founded Influence Inc., which was sold to American Medical Systems Inc. in 1999. Working with Dr. Shlomo Ben-Haim, Mr. Pell founded Biosense Inc. in 1994, which was sold to Johnson and Johnson in 1997. Mr. Pell is currently Chairman and investor in a number of private medical device companies. In 1992 Mr. Pell founded Vision-Sciences, Inc. which merged with Uroplasty in 2015 to become Cogentix Medical. Mr. Pell has a B.S. in Political Science from Brooklyn College.

Kevin Roche

Mr. Kevin H. Roche is an Director of Cogentix Medical, Inc. When Uroplasty merged with Vision-Sciences in March 2015. He became a director of Uroplasty in May 2014. He currently leads Roche Consulting, LLC, a general health care consulting and investing firm providing strategic, operational, legal and other business advice to industry clients. He previously served as the General Counsel of UnitedHealth Group, later becoming CEO of their Ingenix division. Mr. Roche also served as managing partner at Vita Advisors LLC, a healthcare mergers and acquisition advisory firm. Mr. Roche earned his law degree from the University of Minnesota Law School and received his M.B.A. from the University of Minnesota's Carlson School of Business.

Nachum Shamir

Mr. Nachum Shamir serves as Director of the Company. He currently serves as the President and Chief Executive Officer of Luminex Corporation, a publically traded biotechnology company based in Austin, Texas, a position he has held since October 2014. Prior to joining Luminex, Mr. Shamir was the President, Chief Executive Officer and Director of Given Imaging Ltd. (“Given”), a developer, manufacturer and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract which was acquired by Covidien PLC in early 2014. Mr. Shamir held this position from April 2006 to June 2014. Mr. Shamir currently serves on the board of directors of Luminex Corporation and has been serving in such position since October 2014. Mr. Shamir previously served on the board of directors of Given from April 2006 to June 2014. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Howard Zauberman

Mr. Howard I. Zauberman is an Director of the Company. Howard Zauberman has over 30 years of experience as a leader in the medical products industry. Prior to joining the Vision-Sciences, Mr. Zauberman was Vice President of Business Development at Henry Schein, Inc., a leading global healthcare distributor serving office based medical practitioners, from 2005 through 2012. Mr. Zauberman also served as a Special Venture Partner at Galen Partners, a healthcare growth equity and late stage venture capital firm, focused on technology enabled services, medical devices and specialty pharmaceuticals. Prior to this, Mr. Zauberman held senior management positions at ETHICON, Inc. a Johnson & Johnson company and Pfizer, Inc. Mr. Zauberman has a Masters of Engineering Management from Northwestern University, a Bachelor of Science from Columbia University in mechanical engineering and a Bachelors degree from Queens College.

Kenneth Samet

Mr. Kenneth A. Samet is Independent Director of the Company. Mr. Samet currently serves as President and Chief Executive Officer of MedStar Health, a privately-held Maryland-based integrated healthcare delivery system with ten hospitals, 300 distributed care sites and more than $5 billion in annual revenues. He has held several executive roles with MedStar Health or its predecessor organizations over the course of two decades prior to his appointment as President and Chief Executive Officer in 2008. MedStar Health has a network of more than 4,700 affiliated physicians. Mr. Samet was MedStar’s Executive Vice President and Chief Operating Officer from 2000 to 2008, and served as President of Washington Hospital Center, a 900 bed academic medical center, from 1990 to 2000. From the mid-1980s to 1990, Mr. Samet held a variety of leadership positions with the Medlantic Healthcare Group, which ultimately merged with Helix Health in 1998 to create MedStar Health. Mr. Samet currently serves on the board of directors at Georgetown University, the Greater Baltimore Committee, the Economic Club of Washington, United Way of the National Capital Area, Goodwill of Greater Washington and serves on the Executive Committee of the board of the Greater Washington Board of Trade. He is also a member on the Board of Evolent Health, a publicly-traded company that partners with leading health systems to drive value-based care transformation. Mr. Samet received his master’s degree in health services administration from the University of Michigan in 1982.

Basic Compensation